Patents Examined by Christina Marchetti Bradley
-
Patent number: 10004782Abstract: The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.Type: GrantFiled: November 5, 2013Date of Patent: June 26, 2018Assignee: vTv Therapeutics LLCInventors: Maria Carmen Valcarce Lopez, Tung Fong
-
Patent number: 7759311Abstract: A pharmaceutical composition comprising a peptide consisting of Arg-Val-Ala-Val-Ile-Met-Gly-amide-having at least one D-amino acid.Type: GrantFiled: April 2, 2007Date of Patent: July 20, 2010Assignee: Proteotech, Inc.Inventors: Gerardo Castillo, Thomas Lake, Beth Nguyen, Virginia Sanders, Alan D. Snow
-
Patent number: 7749961Abstract: Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.Type: GrantFiled: January 19, 2005Date of Patent: July 6, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit K. Bhardwaj, Francois Bilodeau, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Jean Rancourt
-
Patent number: 7727752Abstract: Compositions, methods, and kits for detecting and monitoring kinase, phosphatase and protein post-translational modification activity are described. The compositions typically include a peptide, a detectable moiety, and a protease cleavage site. Modification of a peptide by a kinase, phosphatase or other protein post-translational modification alters the proteolytic sensitivity of the peptide, resulting in a change of a detectable property of the composition. Panel assays for determining substrates or modulators of kinase, phosphatase or other protein post-translational modification activity are also described.Type: GrantFiled: July 14, 2006Date of Patent: June 1, 2010Assignee: Life Technologies CorporationInventors: Tony A. Klink, Jane A. Beebe, David A. Lasky, Karen M. Kleman-Leyer, Richard Somberg
-
Patent number: 7608444Abstract: The present invention relates to acid-stable proteases of the subtilisin family, their use in animal feed, feed-additives and feed compositions containing such proteases, and methods for the treatment of vegetable proteins using such proteases.Type: GrantFiled: March 8, 2005Date of Patent: October 27, 2009Assignee: DSM IP Assets B.V.Inventors: Peter Rahbek Oestergaard, Carsten Sjoeholm, Anna-Marie Kluenter
-
Patent number: 7598069Abstract: Disclosed are processes for liquefaction and saccharification of polysacharide containing biomasses having high dry matter content (>20%) and preferably possessing large average particle size. The polysaccharide containing biomasses are subject to enzymatic hydrolysis in a mixer that utilizes “free fall” mixing. “Free fall” mixing provides mechanical degradation of the biomass during hydrolysis and, in the case of lignocellulosic biomass, promotes movement of cellulase enzymes along cellulose chains, which improves enzymatic hydrolysis at high dry matter.Type: GrantFiled: April 15, 2008Date of Patent: October 6, 2009Assignee: Inbicon A/SInventors: Claus Felby, Jan Larsen, Henning Jørgensen, Jakob Vibe-Pedersen
-
Patent number: 7582461Abstract: Compositions, methods, and kits for detecting and monitoring kinase or phosphatase activity are described. The compositions typically include a peptide, a detectable moiety, and a protease cleavage site. Modification of a peptide by a kinase or phosphatase alters the proteolytic sensitivity of the peptide, resulting in a change of a detectable property of the composition. Panel assays for determining substrates or modulators of kinase or phosphatase activity are also described.Type: GrantFiled: July 29, 2004Date of Patent: September 1, 2009Assignee: Life Technologies CorporationInventors: Elizabeth A. Werner, Tony A. Klink, Jane A. Beebe, David A. Lasky, Karen M. Kleman-Leyer, Richard Somberg
-
Patent number: 7563772Abstract: Methods of increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. The method for increasing blood flow in such a mammalian brain blood vessel includes administering to a patient in need thereof a therapeutically effective amount of an inhibitor of ? protein kinase C. In certain embodiments, the inhibitor can be chronically administered without causing desensitization of the patient to the inhibitor. Kits for increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided.Type: GrantFiled: December 23, 2005Date of Patent: July 21, 2009Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daria Mochly-Rosen, Rachel Bright
-
Patent number: 7553832Abstract: The present invention relates to compositions (i.e., various organic small molecules as exemplified herein) and methods for the inhibition of protein splicing and especially relates to the inhibition of protein autosplicing of intein-containing proteins. Additionally, the present invention relates to the use of the inhibitors of protein splicing of the invention for the treatment of various diseases including but not limited to tuberculosis. Furthermore, the invention provides the first instance of small molecule inhibitors of protein splicing with drug-like characteristics.Type: GrantFiled: January 24, 2006Date of Patent: June 30, 2009Assignee: Boston Biomedical Research InstituteInventor: Henry Paulus
-
Patent number: 7550557Abstract: Disclosed herein are multilayer films comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polypeptide comprising one or more first amino acid sequence motifs, wherein the one or more first amino acid sequence motifs has a length of 5 to 15 amino acids residues, and wherein the balance of charge in the first amino acid sequence motif at pH 7 is greater than or equal to approximately one-half of the length of the first amino acid sequence motif, wherein the first layer polypeptide is not a homopolymer. Further, a second layer comprises second layer polyelectrolyte comprising a nonprotein polyelectrolyte having a charge opposite that of the first layer polypeptide.Type: GrantFiled: October 25, 2006Date of Patent: June 23, 2009Assignee: Louisiana Tech University Foundation, Inc.Inventor: Donald T. Haynie
-
Patent number: 7544770Abstract: Disclosed herein is a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolye comprises a composite polypeptide comprising one or more surface adsorption regions covalently linked to one or more functional regions forming a single polypeptide chain. The surface adsorption regions comprise one or more amino acid sequence motifs consisting of 5 to 15 amino acid residues. The one or more functional regions comprise 3 to about 250 amino acid residues.Type: GrantFiled: October 25, 2006Date of Patent: June 9, 2009Assignee: Louisiana Tech Foundation, Inc.Inventor: Donald T. Haynie
-
Patent number: 7541340Abstract: The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt?1, except that when a is 1, pt may also be 1.Type: GrantFiled: September 18, 2006Date of Patent: June 2, 2009Assignee: Cornell Research Foundation, Inc.Inventors: Hazel H. Szeto, Shaoyi Liu, Sunghee Cho
-
Patent number: 7538184Abstract: Disclosed herein is a method of controlling the stability of multilayer polypeptide films. A method of controlling the stability of a film, comprises exposing the film to an oxidizing agent or a reducing agent, wherein the film comprises a plurality of layers, the layers comprising alternating oppositely charged polypeptides, wherein a first layer comprises a first layer polypeptide and a second layer comprises a second layer polypeptide, and the first layer polypeptide comprises a sulfhydryl-containing amino acid.Type: GrantFiled: November 16, 2007Date of Patent: May 26, 2009Assignee: Louisiana Tech University FoundationInventor: Donald T. Haynie
-
Patent number: 7534860Abstract: Disclosed herein are films, coatings and microcapsules comprising polypeptides. A thin film, for example, comprises a plurality of layers of polypeptides, the layers comprising alternating oppositely charged polypeptides. A first layer comprises a first layer polypeptide comprising one or more amino acid sequence motifs, wherein the first layer polypeptide is not a homopolymer, is at least 15 amino acid residues long, and has a balance of charge at pH 7 greater than or equal to approximately one-half of the total length of the first layer polypeptide.Type: GrantFiled: November 16, 2007Date of Patent: May 19, 2009Assignee: Louisiana Tech University FoundationInventor: Donald Templeton Haynie
-
Patent number: 7531517Abstract: The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein Y is —NRaRb, —NRcC?ONRaRb, —NRcC?SNRaRb, —NRcC?NRdNaRb, heterocycle, —C?ONRaRb, heterocycle, or aryl; n is 0 to 8; m is 0, or 1; r is 0 to 3; t is 0 to 3; X is O or N; Z is CH2, C?O, C?S or a single bond; Z1 is CO—R2, CS—R2, (CH2)t—R2 or the side-chain of a naturally occuring amino acid;, Z2 is CO—R2, CS—R2 or (CH2)t—R3 or the side-chain of a naturally occuring amino acid; Z3 is CO—R2, CS—R2 or (CH2)t—R4 or the side-chain of a naturally occuring amino acid; Z4 is H, alkyl, alkoxy, or cycloalkyl; R1, R2, R3, and R4 are independently from each other H, OH, SH, NH2, CN, NO2, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkylthio, haloalkyloxy, hydroxyalkyl, hydroxyalkylamino, alkylamino, alkylaryl, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxyalkyl, alkoxy, aryloxy, heteroaryl, aryl, or halogen.Type: GrantFiled: August 10, 2006Date of Patent: May 12, 2009Assignee: 4SC AGInventors: Johann Leban, Martin Kralik
-
Patent number: 7528174Abstract: Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria dysfunction and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels.Type: GrantFiled: August 17, 2006Date of Patent: May 5, 2009Assignee: University of Pittsburgh-Of The Commonwealth System of Higher EducationInventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian E. Kagan, Yulia Y. Tyurina
-
Patent number: 7524925Abstract: Particular aspects provide novel protein interaction reporter (PIR) compounds (e.g., formulas I and II), comprising at least two protein reactive moieties (e.g., N-hydroxysuccinamide), each linked to a reporter moiety (e.g., mass reporter) by a covalent labile bond that is differentially cleavable with respect to peptide bonds (e.g., by a method such as collisional activation in a mass spectrometer, activation by electron capture dissociation (ECD), photoactivation, etc.), wherein the reporter moiety is operatively releasable from the PIR agent upon cleavage of the labile bonds, the released reporter moiety having a characteristic identifying property or label (e.g., m/z value). Particular PIRs comprise a mass reporter moiety, and further comprise an affinity group, (e.g., biotin), linked to the PIR (e.g., to the mass reporter moiety) by a selectively cleavable bone (e.g. photo-labile bond)).Type: GrantFiled: November 18, 2005Date of Patent: April 28, 2009Assignee: Washington State UniversityInventors: James E. Bruce, Xiaoting Tang, Gerhard Munske
-
Patent number: 7524811Abstract: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.Type: GrantFiled: February 28, 2006Date of Patent: April 28, 2009Assignee: Children's Medical Center CorporationInventors: Judah Folkman, Kashi Javaherian, Robert Tjin Tham Sjin
-
Patent number: 7524816Abstract: The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold proteins is BBI.Type: GrantFiled: November 8, 2004Date of Patent: April 28, 2009Assignee: Genencor International, Inc.Inventors: Anthony G. Day, David A. Estell, Christopher J. Murray, Scott D. Power
-
Patent number: RE41288Abstract: It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.Type: GrantFiled: August 6, 2004Date of Patent: April 27, 2010Assignee: Amylin Pharmaceuticals, Inc.Inventors: Thomas R. Coolidge, Mario R. W. Ehlers